Skip to main content
main-content

Connective tissue diseases

Medications

29-05-2020 | COVID-19 | News

Elevated rates of COVID-19 respiratory complications in people with rheumatic diseases

People with rheumatic diseases have a significantly higher risk for developing severe COVID-19 respiratory complications than those without, suggest findings from a US cohort study.

28-05-2020 | Systemic lupus erythematosus | News

Lupus therapies may not impact COVID-19 outcomes

Two case series of patients with systemic lupus erythematosus and SARS-CoV-2 infection explore the association between baseline use of lupus medications and COVID-19 outcomes.

18-05-2020 | COVID-19 | News

Corticosteroid use may be a risk factor for COVID-19 hospitalization in rheumatic disease patients

Study results from the COVID-19 Global Rheumatology Alliance suggest that corticosteroid use at moderate-to-high doses may be associated with an increased risk for hospitalization among people with rheumatic diseases and SARS-CoV-2 infection.

My lupus patient wants to get pregnant: What next?

Ana Rita Cruz-Machado and Laura Andreoli present a case study of a female patient with systemic lupus erythematosus on treatment with teratogenic immunosuppressive drugs who wanted to have a child.

14-05-2020 | Systemic sclerosis | News

Endocannabinoid system modulator shows potential for diffuse cutaneous SSc

The cannabinoid receptor type 2 agonist lenabasum may improve clinical outcomes and underlying disease pathology in patients with diffuse cutaneous systemic sclerosis, show the results of a first-in-human study.

14-05-2020 | Pregnancy | Case study | Article

My lupus patient wants to get pregnant: What next?

Ana Rita Cruz-Machado and Laura Andreoli present a case study of a female patient with systemic lupus erythematosus on treatment with teratogenic immunosuppressive drugs who wanted to have a child.

13-05-2020 | Systemic lupus erythematosus | News

Hydroxychloroquine use does not protect against severe COVID-19 in people with lupus

Data from the COVID-19 Global Rheumatology Alliance provide further evidence against a protective effect of hydroxychloroquine on the development of severe COVID-19 in patients with systemic lupus erythematosus.

05-05-2020 | Systemic sclerosis | News

​​​​​​​World Scleroderma Foundation issues preliminary advice on SSc and COVID-19

The World Scleroderma Foundation has released preliminary guidance to address questions on COVID-19 in patients with systemic sclerosis.

01-05-2020 | Systemic lupus erythematosus | News

Disease characteristics predict belimumab response in SLE

High disease activity, short disease duration, and low baseline damage are associated with an increased response to belimumab in patients with systemic lupus erythematosus, real world study data show.

29-04-2020 | Systemic lupus erythematosus | News

Hydroxychloroquine ‘does not seem to prevent COVID-19’ in people with lupus

The authors of a French case series report the clinical experiences of 17 patients with systemic lupus erythematosus undergoing long-term treatment with hydroxychloroquine who developed COVID-19.

27-04-2020 | COVID-19 | News

COVID-19: FDA warns against chloroquine, hydroxychloroquine use outside specific settings

The US FDA has issued a safety alert warning that chloroquine and hydroxychloroquine for COVID-19 should not be used outside of hospital settings or clinical trials due to an elevated risk for heart rhythm problems with the agents.

24-04-2020 | COVID-19 | News

Rheumatologists, patients report healthcare changes during COVID-19 pandemic

Findings from two questionnaire studies suggest that a substantial proportion of rheumatology patients have experienced changes to their disease management since the emergence of COVID-19.

20-04-2020 | COVID-19 | News

First data from the COVID-19 Global Rheumatology Alliance released

The COVID-19 Global Rheumatology Alliance has released preliminary data on 110 individuals with rheumatic disease and comorbid COVID-19.

08-04-2020 | COVID-19 | News

ACR advises on resource allocation during COVID-19 pandemic

The ACR has issued guiding principles for the allocation of hydroxychloroquine, IL-1 and 6 antagonists, JAK inhibitors, and eculizumab during the COVID-19 pandemic.

07-04-2020 | Lupus nephritis | News

EULAR, ERA–EDTA issue guidelines for managing lupus nephritis

EULAR and the Renal Association–European Dialysis and Transplant Association have issued updated recommendations for the management of lupus nephritis.

07-04-2020 | Systemic lupus erythematosus | Feature | Article

In pursuit of new lupus therapies: The importance of trial endpoints

Eric Morand explores the reasons why the TULIP-1 and TULIP-2 trials of anifrolumab found different primary results, and discusses the search for optimal endpoints in lupus trials.

06-04-2020 | Sjögren’s syndrome | News

Support for further study of leflunomide–hydroxychloroquine for primary Sjögren’s syndrome

Findings from RepurpSS-I, a small phase 2a trial, suggest that leflunomide–hydroxychloroquine combination therapy has a favorable safety profile and gives rise to a clinical response in patients with primary Sjögren’s syndrome.

Rheumatologists urge caution on chloroquine, hydroxychloroquine use for COVID-19

Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.

03-04-2020 | COVID-19 | News

Mild COVID-19 reported in a patient with SSc–ILD

The authors of a case report discuss the experience of a patient with systemic sclerosis-associated interstitial lung disease who developed a mild form of COVID-19.

03-04-2020 | COVID-19 | Highlight | News

Rheumatologists urge caution on chloroquine, hydroxychloroquine use for COVID-19

Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.

Image Credits